Woodline Partners LP Arcus Biosciences, Inc. Transaction History
Woodline Partners LP
- $9.97 Billion
- Q2 2024
A detailed history of Woodline Partners LP transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 4,245,221 shares of RCUS stock, worth $65.3 Million. This represents 0.65% of its overall portfolio holdings.
Number of Shares
4,245,221
Previous 2,883,657
47.22%
Holding current value
$65.3 Million
Previous $54.4 Million
18.76%
% of portfolio
0.65%
Previous 0.52%
Shares
13 transactions
Others Institutions Holding RCUS
# of Institutions
207Shares Held
49MCall Options Held
173KPut Options Held
151K-
Black Rock Inc. New York, NY9.76MShares$150 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$80.9 Million0.0% of portfolio
-
State Street Corp Boston, MA3.06MShares$47 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.83MShares$28.2 Million0.08% of portfolio
-
Invus Financial Advisors, LLC New York, NY1.61MShares$24.8 Million27.51% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.11B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...